The effects of age on carbamazepine pharmacokinetics and adverse effects.
- 1 December 1986
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 22 (6), 725-728
- https://doi.org/10.1111/j.1365-2125.1986.tb02965.x
Abstract
The pharmacokinetics and effect of single oral doses of carbamazepine (400 mg) were compared in a group of six young volunteers aged between 20 and 25 years, and a second group of five elderly volunteers aged between 66 and 84 years. No age related changes in salivary or plasma pharmacokinetics or in psychomotor function were detected.This publication has 10 references indexed in Scilit:
- Value of saliva samples in monitoring carbamazepine concentrations in epileptic patientsActa Neurologica Scandinavica, 2009
- Drug Disposition in the Elderly: A Review of the Critical FactorsJournal of the American Geriatrics Society, 1984
- Saliva carbamazepine levels in children before and during multiple dosing.British Journal of Clinical Pharmacology, 1982
- Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11‐epoxide in epileptic patients.British Journal of Clinical Pharmacology, 1981
- Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serumCancer Cell, 1980
- Psychomotor function and psychoactive drugs.British Journal of Clinical Pharmacology, 1980
- Measurement of carbamazepine and its epoxide metabolite by high-performance liquid chromatography, and a comparison of assay techniques for the analysis of carbamazepine.Clinical Chemistry, 1977
- Distribution and elimination kinetics of carbamazepine in manEuropean Journal of Clinical Pharmacology, 1975